CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / As we close out the week of the first few days of the new year, The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the world. As demand for qualitative healthcare options increases at a rapid rate, so do opportunities for companies to invest and pioneer new technologies to improve the quality of care for individuals suffering from numerous diseases and ailments. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (PHGRF) (PHGI), Flex Pharma, Inc. (NASDAQ: FLKS), Ampliphi Biosciences Corp (NYSE American: APHB), and Histogenics Corp (NASDAQ: HSGX) are 4 healthcare stocks worth checking out on Friday.
Premier Health Group (PHGRF) (PHGI) enjoyed impressive gains as shares closed out Thursday's trading at $0.66 per share, up more than 7% from December 27's close of $0.62 per share. Over the course of the past thirty days, Premier has seen a period of bullish trading as its shared climbed over 30% this past month. The Company has seen significant growth in the month of December following momentum gained from several key announcements regarding two separate LOI agreements.
Earlier in December, Premier Health Group (PHGRF) (PHGI) announced that, in an effort to advance its overarching strategy to cover all major verticals associated with primary care as well as develop innovative approaches that combine human skill-based expertise with emerging technologies, it had signed a binding LOI to acquire all outstanding securities of Cloud Practice, Inc.
Presently, Cloud Practice offers cloud-based electronic medal records software for medical professionals across Canada. As stated in their recent financial reports, Cloud Practice is EBITDA positive, resulting in immediate cash flow generation and earnings accretion for Premier Health.
Dr. EssamHamza, CEO of Premier Health Group (PHGRF) (PHGI), said, ''We are ecstatic at the opportunity to build on ourpatient centric technology platform through the integration of Cloud Practice's suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare. We believe that this partnership will help facilitate our vision of integrating telemedicine, online bookingand other premium services with our electronic medical record (EMR) system.''
Flex Pharma, Inc. (NASDAQ: FLKS), and Salarius Pharmaceuticals, a clinical-stage oncology company targeting the epigenetic causes of cancers, announced on Friday that the two companies have entered into a definitive merger agreement under which privately-held Salriaus will merge with a wholly-owned subsidiary of Flex Pharma. According to the announcement, management believes that the proposed transaction will position the combined company to recognize multiple value inflection points based on Salarius' clinical pipeline.
In a press release regarding the merger, Dr. William McVicar, CEO of Flex Pharma, said, ''After completing a comprehensive and highly competitive selection process, we are confident that the proposed transaction with Salarius offers the best opportunity for significant near-and long-term value creation. We were impressed by the compelling science supportingSalarius' novel drug, as well as the company's strong financial position and management team. Based on our diligence, we believeSalarius could be poised to advance multiple potential product opportunities that address significant unmet needs in oncology.''
AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company determined to create therapeutics for antibiotic-resistant infections and C3J Therapeutics, Inc., announced on Friday that thecompanies have entered into a definitive agreement under which a wholly owned subsidiary of AmpliPhi will merge with C3J in an all-stock transaction.
Todd. R Patrick, Presidentand CEO of C3J, said, ''We are delighted with the prospect of consummating this merger with AmpliPhi. We believe the depth of knowledge that AmpliPhi has developed through human dosing of natural phage therapeutics complements C3J's capabilities as a leader in the development of synthetic phage through its proprietary phage engineering platform. Synthetic phage offers enhanced antimicrobial properties that improve pharmacology, limit the emergence of phage-resistant bacteria and create potential opportunities for IP protection for best-in-class therapeutics.''
Histogenics Corporation (NASDAQ: HSGX) found itself in headlines in late-December when the Company provided an update on their NeoCart regulatory pathway based on discussions with the US Food and Drug Administration. According to the announcement, the feedback provided by the FDA, at the time, indicated that an additional trial would need to be completed before it would accept submission of a Biologics License Application for NeoCart.
The Company Histogenics determined not to proceed at that time with its earlier plans to conduct a stockholder meeting to increase its authorized shares and a reverse split, for which it had filed a preliminary proxy statement with the Securities Exchange Commission (the SEC) on October 18, 2018.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for and were paid ''500,000'' shares of restricted common shares (as of 1/4/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information Please click here for full disclaimer.